Highest-materiality recent filing
Novanta Q2 2026 revenue up 10% to $266M; adjusted EPS up 17% to $0.89
GAAP revenue $265.8M, up 10% YoY from $241.0M; net income $12.5M vs $4.5M.
Acquired Riverpoint Medical for ~$1.2B cash at closing; additional $250M milestone payment due by Jan 8, 2027.
Novanta raises $300M via private placement of 2.1M shares at $140 each
Sold 2,142,857 common shares at $140.00 each for gross proceeds of ~$300M.
Upfront cash consideration of $1.2B; milestone payment of $250M due Q1 2027.
Novanta shareholders elect all nine directors and approve executive compensation at annual meeting
All nine director nominees elected; votes for ranged from 30.98M to 31.74M.
Novanta enters $200M delayed draw term loan facility maturing 2030
Second Amendment to Credit Agreement establishes $200M delayed draw term loan commitments.
Novanta Q1 revenue up 10% to $258M, adjusted EPS $0.81, net income $21M
GAAP revenue $257.7M (+10% YoY); GAAP net income $21.1M (flat).
Novanta Q4 revenue $258M (+9% YoY), adjusted EPS $0.91 (+20% YoY)
GAAP revenue $258.3M in Q4 2025, up 9% YoY; GAAP diluted EPS $0.45.
Novanta appoints Alexander Manganiello as General Counsel and Corporate Secretary
Appointed Alexander Manganiello as General Counsel and Corporate Secretary effective December 1, 2025.
Novanta revises Q4 and FY 2025 adjusted EPS guidance lower after equity issuance
Q4 2025 non-GAAP adjusted diluted EPS now $0.84-$0.91 (prior $0.87-$0.93).
Novanta closes $632.5M tangible equity units offering; amends credit agreement
Issued 12,650,000 Units at $50.00 each, including full over-allotment exercise.
Novanta Q3 2025 revenue up 1.4% to $247.8M; GAAP EPS drops to $0.30 from $0.53
GAAP revenue $247.8M (+1.4% YoY); GAAP net income $10.7M vs $19.2M in Q3 2024.
Novanta board authorizes additional $200M share repurchase; total capacity $231M
Board approved $200M additional common share repurchase authorization on Sept 17, 2025.
Novanta director Barbara Hulit resigns from board, effective Nov 1, 2025
Barbara Hulit resigned from Novanta's Board, effective November 1, 2025.
Novanta Q2 2025 GAAP EPS falls 68% to $0.12; Adj. EPS rises to $0.76 on 2% revenue growth
GAAP revenue $241.0M (+2% YoY); GAAP net income $4.5M vs $13.8M; GAAP diluted EPS $0.12 vs $0.38.
Novanta General Counsel & Corporate Secretary Michele D. Welsh to depart July 18, 2025
Michele D. Welsh will no longer serve as General Counsel and Corporate Secretary effective July 18, 2025, or earlier if mutually agreed.
Novanta enters $1.0B credit facility maturing 2030; replaces $392.4M existing debt
Facility includes €65.31M euro term loan, $75M US term loan, $850M revolver; maturity June 2030.
Novanta announces restructuring plan with $20M-$25M pre-tax charges
Pre-tax charges estimated at $20M-$25M from employee-related costs, manufacturing moves, contract terminations, and asset write-offs.
Novanta holds annual meeting; all director nominees elected, advisory votes approved
All nine director nominees elected with substantial support (each received >31M votes for).
Novanta Q1 rev +1% to $233M; GAAP NI +45%; adj EPS flat $0.74
GAAP revenue $233.4M (+1% YoY); GAAP net income $21.2M (+45%); GAAP diluted EPS $0.59 vs $0.41.
Novanta Reports Q4 and Full Year 2024 Results: Revenue Up 13% in Q4, 8% for Full Year
Q4 2024 revenue increased 13% to $238M; GAAP diluted EPS $0.46, adjusted EPS $0.76.
Novanta recasts segment reporting into Automation Enabling Technologies and Medical Solutions
Two new segments replace prior three-segment structure (Precision Medicine & Manufacturing, Robotics & Automation, Medical Solutions).
Novanta Q3 2024 revenue up 10% to $244M; GAAP EPS $0.53 vs $0.59 a year ago
Revenue $244.4M, +10% YoY from $221.5M.
Novanta appoints John Burke as Chief Accounting Officer; Peter Chang departs after 13 years
John Burke, former VP Global Accounting, named CAO effective Aug 22, 2024, succeeding Peter Chang.
Novanta Q2 2024 revenue up 2.8% to $236M, but GAAP EPS falls 34% to $0.38
Revenue $235.9M (+2.8% YoY); GAAP net income $13.8M vs $20.9M in Q2 2023.
Novanta announces departure of CHRO Brian Young effective Nov 1, 2024
Brian Young, Chief Human Resources Officer, to leave Novanta effective Nov 1, 2024 or earlier as agreed.
Novanta director Katherine Owen resigns; Mary Kay Ladone elected to board
Katherine A. Owen resigned from board and Audit Committee on July 11, 2024, effective immediately; no disagreement cited.
Novanta shareholders approve all proposals at 2024 annual meeting
94.33% of outstanding shares (33.9M) were present or represented at the May 8, 2024 AGM.
Novanta Q1 2024 revenue up 5.4% to $231M; GAAP net income down to $14.7M
GAAP revenue $230.9M vs $219.1M YoY; GAAP net income $14.7M vs $18.3M.
Novanta replaces PwC with Deloitte as independent auditor after competitive process
Board requested PwC's resignation effective March 14, 2024, engaging Deloitte as successor.
Novanta reports Q4 revenue $211.6M, FY 2023 GAAP EPS $2.02, adjusted EPS $3.02
Q4 2023 revenue $211.6M (down 3% YoY); GAAP diluted EPS $0.35 vs $0.42.
Novanta completes acquisition of Motion Solutions; draws $198M under credit facility
Acquired 100% of Motion Solutions capital stock for ~$192.2M using revolving credit facility draw of $198M.
Novanta to acquire Motion Solutions for $189M cash; expected close Q1 2024
Purchase price $189M in cash, financed with cash on hand and revolving credit facility.
Novanta reports Q3 2023 GAAP revenue of $221.5M, adjusted EPS $0.85
GAAP revenue $221.5M vs $223.0M YoY; GAAP net income $21.2M vs $22.5M.
Novanta Q2 revenue up 7% to $229.5M; GAAP EPS $0.58, adj. EPS $0.80
GAAP revenue $229.5M, +7% YoY from $215.4M; operating income $32.2M vs $23.3M.
All eight director nominees elected: Lonny Carpenter, Matthijs Glastra, Barbara Hulit, Maxine Mauricio, Katherine Owen, Thomas Secor, Darlene Solomon, Frank Wilson.
Novanta Q1 2023 revenue up 7% to $219M; GAAP EPS $0.51, adjusted EPS $0.74
GAAP revenue $219.1M (+7% YoY); GAAP net income $18.3M vs $18.8M YoY.
Novanta discloses minimal SVB exposure: cash <$400k, 10% of credit facility
SVB is one of seven lenders under Novanta's $695M credit agreement, representing about 10% of total commitments.
Novanta reports Q4 and FY2022 results; details not in filing text
Novanta announced Q4 and full year 2022 financial results on March 1, 2023.
Novanta Q3 revenue up 26% to $223M; raises FY2022 guidance
GAAP revenue $223M, +26% YoY; diluted EPS $0.63, +66% YoY.
Novanta Q2 2022: revenue up 29% to $215M; EPS $0.49; raises full-year guidance
GAAP revenue $215.4M (+29% YoY); operating income $23.3M.
Director Ira Lamel resigns; Barbara Hulit elected to Novanta board
Ira J. Lamel resigned as director of Novanta effective July 26, 2022.
Novanta names Michele D. Welsh as General Counsel and Corporate Secretary
Appointment effective July 11, 2022; Welsh will lead global legal, regulatory, corporate secretary, and EHS teams.
Novanta director Brian King resigns; Dr. Darlene Solomon appointed to board
Brian King resigned as director effective June 28, 2022.
Novanta shareholders elect all 8 directors, approve say-on-pay and auditor at AGM
All eight director nominees elected; Thomas Secor received the most withhold votes (2,088,251).
Novanta Q1 2022 revenue up 26% to $204M; adjusted EPS $0.73
GAAP revenue $204.2M, up 26% YoY from $162.6M; GAAP net income $18.8M.
Novanta extends credit facility maturity to 2027, increases accordion to $350M, adopts SOFR
Maturity date extended from Dec 31, 2024 to March 10, 2027.
Novanta FY2021 revenue $707M (+20% YoY), adjusted EPS $2.62 (+34% YoY)
Full year 2021 GAAP revenue of $706.8M, up 20% from $590.6M in 2020.
Director Deborah DiSanzo resigns from Novanta board effective Feb 28, 2022
Deborah DiSanzo resigns from Board to focus on her role as President of Best Buy Health.
Novanta Q3 revenue $177.7M (+24% YoY); adj. EPS $0.75, raises FY guidance
GAAP revenue $177.7M, up 24% from $142.9M in Q3 2020.
Mr. Burke succeeds Peter Chang, Chief Accounting Officer and Corporate Controller of the Company, who departed from the role effective August 22, 2024.
On August 22, 2024, John Burke, formerly Vice President of Global Accounting for Novanta Inc. (the “Company”), was appointed Chief Accounting Officer of Novanta Inc. and assumed the role of principal accounting officer.
On August 1, 2024, Novanta Inc. (the “Company”) announced that Brian Young, Chief Human Resources Officer (“CHRO”) of the Company, would no longer serve as the CHRO, effective on November 1, 2024, or such earlier date as may be agreed between Mr. Young and determined by the Company.
On July 11, 2024, Katherine A. Owen resigned as a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”) and the Audit Committee of the Board, effective immediately.
On July 11, 2024, the Board elected Mary Katherine (Mary Kay) Ladone to the Board to fill the vacancy created by Ms. Owen’s resignation, effective July 11, 2024.
On July 26, 2022, the Board of Directors (the “Board”) of the Company elected Barbara B. Hulit to the Board to fill an existing vacancy, effective July 26, 2022.
On July 26, 2022, Ira J. Lamel resigned as a director of Novanta Inc. (the “Company”), effective immediately.
On June 28, 2022, the Board of Directors (the “Board”) of the Company elected Darlene J. S. Solomon, Ph.D., to the Board to fill an existing vacancy, effective June 28, 2022.
On June 28, 2022, Brian King resigned as a director of Novanta Inc. (the “Company”), effective immediately.
On November 6, 2021, Deborah DiSanzo, a member of the Board of Directors (the “Board”) of Novanta Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective February 28, 2022, in order to focus her attention on her responsibilities as the President of Best Buy Health and other professional responsibilities.
Max materiality 0.90 · Median 0.55 · Most common event earnings